As of 2026-04-13, the EV/EBITDA ratio of Celldex Therapeutics Inc (CLDX) is -7.46. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLDX's latest enterprise value is 2,117.35 mil USD. CLDX's TTM EBITDA according to its financial statements is -283.99 mil USD. Dividing these 2 quantities gives us the above CLDX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 18.4x | 16.2x |
| Forward P/E multiples | 18.0x - 20.2x | 19.1x |
| Fair Price | (76.27) - (78.06) | (74.86) |
| Upside | -336.6% - -342.1% | -332.2% |
| Date | EV/EBITDA |
| 2026-04-08 | -7.50 |
| 2026-04-07 | -7.25 |
| 2026-04-06 | -7.25 |
| 2026-04-02 | -7.18 |
| 2026-04-01 | -7.23 |
| 2026-03-31 | -7.33 |
| 2026-03-30 | -6.81 |
| 2026-03-27 | -7.00 |
| 2026-03-26 | -7.34 |
| 2026-03-25 | -7.32 |
| 2026-03-24 | -7.21 |
| 2026-03-23 | -7.35 |
| 2026-03-20 | -7.14 |
| 2026-03-19 | -6.94 |
| 2026-03-18 | -6.59 |
| 2026-03-17 | -6.85 |
| 2026-03-16 | -6.98 |
| 2026-03-13 | -6.82 |
| 2026-03-12 | -6.90 |
| 2026-03-11 | -7.22 |
| 2026-03-10 | -7.20 |
| 2026-03-09 | -7.10 |
| 2026-03-06 | -6.80 |
| 2026-03-05 | -6.78 |
| 2026-03-04 | -6.82 |
| 2026-03-03 | -6.68 |
| 2026-03-02 | -6.93 |
| 2026-02-27 | -6.95 |
| 2026-02-26 | -7.08 |
| 2026-02-25 | -7.12 |
| 2026-02-24 | -5.72 |
| 2026-02-23 | -5.60 |
| 2026-02-20 | -5.29 |
| 2026-02-19 | -5.42 |
| 2026-02-18 | -5.29 |
| 2026-02-17 | -5.28 |
| 2026-02-13 | -5.29 |
| 2026-02-12 | -5.42 |
| 2026-02-11 | -5.66 |
| 2026-02-10 | -5.67 |
| 2026-02-09 | -5.71 |
| 2026-02-06 | -5.47 |
| 2026-02-05 | -5.19 |
| 2026-02-04 | -5.59 |
| 2026-02-03 | -5.80 |
| 2026-02-02 | -5.68 |
| 2026-01-30 | -5.66 |
| 2026-01-29 | -5.69 |
| 2026-01-28 | -5.70 |
| 2026-01-27 | -6.05 |